Current treatments can be invasive, can require a hospital stay, and may produce severe side effects, including pain and a narrowing of the esophagus. CryoSpray Ablation (TM) is an outpatient procedure, with patients generally resuming normal activities the same or next day.
MIPS funding enabled CSA Medical to team with Dr. Greenwald in a clinical trial at the University of Maryland Medical Center. While MIPS projects typically last one year, CSA Medical's was so successful that the company stopped the trial within nine months and decided to pursue an expanded, multi-center trial.
In the past 18 months, CSA Medical has grown from one to 16 employees, raised $12 million in financing, acquired FDA clearance for its product, obtained certification to market its product in Europe, began a national, 20-center clinical trial, and commercially launched its CryoSpray Ablation (TM) product.
"The MIPS funding allowed us to validate our early clinical trial data in a major university hospital with a prominent physician," said Askew. "It was also a catalyst for our commercialization process."
More than 60 physicians around the country have been trained on CryoSpray Ablation (TM), while 16 leading hospitals are currently treating patients using the device. CSA Medical plans to add about 30 additional treatment centers in the next six months.
"I think CryoSpray Ablation will gain a firm foothold in gastroenterology for the destruction of cancer and precancerous lesions in the GI tract," says Dr. Greenwald. "It holds a unique position in its ability to treat non-flat lesions that other technologies are lacking."
CSA Medical plans to investigate CryoSpray Ablation (TM) for treating other diseases.
About MIPS (http://www.mips.umd.edu)
The MTECH Maryland Industrial Partn
|SOURCE Maryland Technology Enterprise Institute|
Copyright©2007 PR Newswire.
All rights reserved